secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0000950170-22-015527
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q2 NUPLAZID sales $134.6M (+17% YoY); NDA filed for trofinetide in Rett syndrome
--------------------------------------------------------------------------------

- Q2 net loss $34.0M ($0.21/share) vs $43.9M loss in Q2 2021; six-month loss $147.1M.
- R&D expense $75.6M vs $56.9M YoY; SG&A $89.9M vs $96.8M on lower promo costs.
- NDA submitted to FDA for trofinetide for Rett syndrome; CRL received for pimavanserin in Alzheimer's psychosis.
- Discontinued development of ACP-044 (pain) and ACP-319 (M1 PAM) based on data review.
- 2022 NUPLAZID revenue guidance narrowed to $510-540M from $510-560M; R&D guidance reduced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000095017022015527/0000950170-22-015527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000095017022015527/acad-20220808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer